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Abstract
Background: Mitotically active cellular fibroma (MACF) of the ovary, characterized by relatively high mitotic activity
without severe atypia, represents a relatively new disease entity. MACF is categorized as a benign ovarian tumor.
However, due to a limited number of case reports, its clinical and pathological features and optimum management
remains largely undetermined. Herein, we report on a rare case of MACF that grew rapidly in size and was
diagnosed on detailed pathological examination.
Case presentation: A 44-year-old Japanese woman, who detected a myoma-like lesion 1-year earlier, was referred
to our hospital when the follow-up examination demonstrated that the mass had increased in size. Magnetic
resonance imaging revealed a T1 isointense and T2 hyperintense tumor (11 cm in diameter) in the right pelvic
cavity. Laparoscopy confirmed the presence of a right ovarian tumor and laparoscopic right adnexectomy was
performed. The tumor cells consisted of dense cellular proliferations of spindle fibroblast-like cells without
significant cytological atypia. The mitotic activity index was estimated at >15 mitotic figures per 10 high-power
fields. Reticulin staining and FOXL2 mutation analysis excluded the possibility of an adult granulosa cell tumor, and
the patient was diagnosed with a MACF of the ovary.
Conclusions: To the best of our knowledge, we are the first to report on a case of rapid growth of a MACF of the
ovary during follow-up. When an increase in the size of a solid ovarian mass is detected, a MACF should be
considered as a differential diagnosis.
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Background
Ovarian fibrous tumors were previously classified as be-
nign fibromas or malignant fibrosarcomas, according to
the World Health Organization’s classification of tumors
of the breast & Female Genital Origans [1]. Ovarian cel-
lular fibromas were defined as having a mitotic figure of
<3 per 10 high-power fields without severe nuclear aty-
pia, and fibrosarcomas were defined as having a mitotic
figure of ≥4 per 10 high-power fields with severe nuclear
atypia [1]. Generally, the prognosis of patients with
fibrosarcomas is extremely poor [2]. However, there have
been a minority of cases where the patient was catego-
rized as having fibrosarcoma with mild nuclear atypia,
despite a high mitotic activity. These patients were asso-
ciated with a relatively favorable prognosis [3–8]. In
2006, Irving et al. [9] defined these types of tumors as
mitotically active cellular fibromas (MACFs), thus, dis-
tinguishing them from fibrosarcomas. Accordingly,
MACFs have now been included under the heading of fi-
bromas in the 2014 World Health Organization classifi-
cation system [10]. MACFs are defined as having a
mitotic figure of <3 per 10 high-power fields without se-
vere nuclear atypia and fibrosarcomas are defined as
having a mitotic figure of ≥4 per 10 high-power fields
with severe nuclear atypia [10]. Several case reports have
been published since MACFs were defined [11–16].
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MACFs are associated with a more favorable prognosis
than fibrosarcomas, with limited data on long-term sur-
vival rates available [17]. However, the natural history of
MACFs is still largely unknown and suitable guidelines
for diagnosing and treating this condition are lacking.
Herein, we report on the clinical and histopathological
characteristics of a rare case of rapid growth of a MACF
of the ovary that almost doubled in size during a 1-year
follow-up period and provide a review of the literature.
Case presentation
A 44-year-old Japanese woman underwent a medical
examination for health check reasons at her local hos-
pital. An ultrasound scan revealed a uterine myoma-like
lesion, 5.9 cm in diameter. The patient revisited the hos-
pital 12-months later for a follow-up examination. In
that time, the lesion had increased to approximately
twice its size. The patient was referred to our clinic for a
detailed examination. At the first internal examination,
the body of the uterus was enlarged to the size of a new-
born head; cervical and vaginal discharge was unremark-
able. The adnexa were not palpable on both sides. The
patient’s blood test results were normal. Transvaginal
ultrasonography detected an isoechoic solid mass with
an ill-defined boundary between the lesion and the
uterus (Fig. 1a). A tumor, 110 × 90 × 80 mm in size, was
revealed in the right pelvic cavity by magnetic resonance
imaging. The tumor exhibited a slightly lobular pattern
with smooth margins. The internal mass had a density
similar to that of myometrium on abdominal, T1-
weighted magnetic resonance imaging and a low density
on T2-weighted magnetic resonance imaging in the
horizontal plane (Fig. 1b). Several flow void regions (a
bridging vascular sign) were detected between the lesion
and the uterus. These findings suggested a subserous
myoma. However, the continuity of the lesion and the
uterus was unclear. Since we were unable to identify the
right ovary, a fibroma/thecoma of the right ovary was
considered as a differential diagnosis (Fig. 1c). The left
ovary did not exhibit any abnormalities. At this point, a
preliminary clinical diagnosis of subserous myoma was
made and a laparoscopic myomectomy was planned.
The laparoscopic findings demonstrated a 10-cm right
ovarian mass without intra-abdominal adhesion or rup-
ture of the tumor. The uterus and left appendages were
normal in size (Fig. 2). A laparoscopic right adnexect-
omy was subsequently performed. The ascitic fluid was
serous, and the cytological evaluation was negative.
Macroscopically, the cut surface of the tumor was
homogeneous and solid in appearance with a yellowish-
white pigment. Necrosis and hemorrhage were absent
within the tumor (Fig. 3a, b). Microscopic images are
depicted in Fig. 4a–d. The capsule of the tumor was in-
tact without necrosis and hemorrhage (Fig. 4a). The
tumor cells consisted of dense cellular proliferations of
spindle fibroblast-like cells, arranged in a fascicular
structure, without significant cytological atypia (Fig. 4b).
In addition, a portion of the tumor cells proliferated in a
trabecular pattern and a collagen band was distributed
around the stroma (Fig. 4c). The tumor was composed
of cells with ovoid to spindle-shaped nuclei and a scant
cytoplasm. Some of the nuclei had a nuclear groove. No
severe cytological atypia was detected. The mitotic
Fig. 1 Preoperative transvaginal ultrasonography (a) detected an isoechoic solid mass in the right pelvic cavity (approximately 10 cm in size) with an
ill-defined boundary between the lesion and the uterus, and T2-weighted magnetic resonance imaging of the ovarian tumor in (b) the horizontal and
(c) the sagittal planes
Fig. 2 Laparoscopic findings. The uterus was of a normal size and
the mass was a right ovarian tumor
Matsuda et al. Diagnostic Pathology  (2016) 11:101 Page 2 of 6
activity index was estimated at >15 mitotic figures per
10 high-power fields (Fig. 4d). Pathological differential
diagnoses included a cellular fibroma, fibrosarcoma and
adult granulosa cell tumor (AGCT).
Immunohistochemical staining was positive for vimen-
tin, muscle-specific actin, alpha-smooth muscle actin,
alpha-inhibin and progesterone receptor (Fig. 5a–e), and
negative for calretinin, epithelial membrane antigen, des-
min, estrogen receptor, CD10, CD99, chromogranin A,
synaptophysin and tumor protein p53. The Ki-67/MIB-1
labeling index was 9.5 % (Fig. 5f ). Reticulin staining
showed reticular fibers surrounding each cell (Fig. 5g).
This was not a typical feature of AGCT. We further ana-
lyzed genomic DNA (isolated from formalin-fixed,
paraffin-embedded tumor tissue sections) for a FOXL2
c.402C > G (p.C134W) point mutation that is observed
in the majority of AGCT patients [18, 19]. The FOXL2
mutation was detected in the AGCT case used as a posi-
tive control, but was absent from our case and the nega-
tive control (Fig. 6). Because necrosis and hemorrhage
were not detected macro- or microscopically, a fibrosar-
coma was ruled out. After performing the differential
diagnoses outlined above, a final diagnosis of MACF was
confirmed. Having obtained written informed consent,
we evaluated the patient’s risk of recurrence. Based on
our recommendation and the preference of the patient,
we performed radical surgery (simple hysterectomy, left
adnexectomy and omentectomy). The patient is under-
going regular follow-up. Recurrence of the tumor has
not been observed in the 2-year postsurgical period.
Fig. 3 Macroscopic image of the right ovarian tumor. The cut surface of the tumor was homogeneous and solid in appearance with a
yellowish-white pigment
Fig. 4 Histopathological findings of the right ovarian tumor. a The capsule of the tumor was intact without necrosis and hemorrhage; (b) dense
cellular proliferations of spindle fibroblast-like cells, arranged in a fascicular structure with ovoid to spindle-shaped nuclei and a scant cytoplasm,
and (c) tumor cell proliferations in a trabecular pattern with a collagen band distributed around the stroma; and (d) absence of significant cyto-
logical atypia. The mitotic activity index was estimated at >15 mitotic figures per 10 high-power fields (hematoxylin and eosin staining; original
magnification [a] × 20, [b, c] × 100, and [d] × 400)
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Discussion
MACF was first defined by Irving et al. [9] in 2006,
based on a review of 75 cellular fibroma cases. The au-
thors reported that the majority of MACF patients have
a good clinical course compared to fibrosarcoma pa-
tients. However, there was a case where death was asso-
ciated with peritoneal adhesion and capsule rupture and
Irving et al. [9] could not necessarily conclude it to be a
benign tumor. Therefore, pathological differential diag-
noses of ovarian fibromatous tumors (including cellular
fibroma, MACF and fibrosarcoma) are important since
they influence decision-making, as well as, the prognosis
of different treatment strategies.
Only six MACF cases have been reported since a def-
inition of MACF was established in 2006 (Table 1). The
natural history of MACF is still largely unknown. Five
(83.3 %) of these recently reported cases were given a
diagnosis of ovarian tumor. However, there has not been
a single case where a diagnosis of MACF was confirmed
preoperatively. Because there are no clinically useful
serum tumor markers for MACF, or characteristic im-
aging findings, a preoperative diagnosis of MACF re-
mains challenging at this time. There was a case report
where the size of the tumor did not change during 10-
years of follow-up [16]. In contrast, there was also a case
report where a recurrent tumor, 8 cm in diameter, was
detected in the pararectal region after 6 months of
follow-up. In our case, a mass of 6 cm was found to have
almost doubled in size, to 10 cm, during a 1-year follow-
up period. Thus, when a solid ovarian tumor increases
in size, even though malignancy findings are not found
considering preoperative serum tumor marker values or
imaging findings, MACF may well be included as a can-
didate for the differential diagnosis. In the 6 case reports
published since the paper by Irving et al. [9], 5 patients
(83.3 %) underwent open surgery, including a unilateral
salpingo-oophorectomy in 2 patients [11, 13] and a rad-
ical operation (bilateral oophorectomy and hysterec-
tomy) in 3 patients [12, 14, 15]. One patient treated with
laparoscopic oophorectomy was reported by Yamada
et al. [16] in 2015. However, because the follow-up
Fig. 5 Immunohistochemical analysis of the right ovarian tumor exhibiting positivity for (a) vimentin, (b) muscle-specific actin, (c) alpha-smooth
muscle actin, (d) alpha-inhibin and (e) estrogen receptor. f The Ki-67/MIB-1 labeling index was 9.5 % (original magnification × 200). g Reticulin
staining showed reticular fibers surrounding each tumor cell (original magnification × 100)
Fig. 6 Analysis of a c.402C > G point mutation in the FOXL2 gene in
(a) the normal control (negative; blue circle), (b) the adult granulosa
cell tumor patient used as a positive control (positive; red circle), and
(c) our patient with rapid growth of mitotically active cellular
fibroma (negative; blue circle)
Matsuda et al. Diagnostic Pathology  (2016) 11:101 Page 4 of 6
period remains limited, the long-term prognosis has yet
to be determined. No standard treatment for MACF cur-
rently exists, although overtreatment should be avoided
in women requiring preservation of fecundity [2, 3].
Zong et al. [15] suggested that other risk factors, such as
tumor size, growth rate and Ki-67 positivity, should be
considered. As our case grew rapidly, the tumor size was
relatively large, and the patient did not wish to conceive,
we concluded that radical surgery was a reasonable op-
tion. Moreover, because there were no signs of recur-
rence, complete resection was not necessary for
administering chemotherapy for the tumor associated
with capsule rupture and peritoneal adhesion [15]. In
contrast, there was a case where recurrence occurred 5-
years after surgery [12]. Therefore, we believe long-term
follow-up is necessary.
MACFs are defined as cellular fibromas with a high
mitotic activity index (≥4 mitotic figures per 10 high-
power fields) and mild to moderate nuclear atypia [10].
The differential diagnosis with fibrosarcoma is possible
for nuclear atypia and the presence of necrosis and
hemorrhage. There is a difficult case for the histological
differential diagnosis of cellular fibroma and AGCT (es-
pecially the diffuse type) [20]. Cellular fibromas and
AGCTs are represented by the sex cord-stromal tumors
[1, 10]. However, the majority of borderline malignant
sex cord-stromal tumors are AGCTs [21]. Therefore, the
differential diagnosis with commonly benign cellular fi-
broma is important.
The FOXL2 c.402C > G (p.C134W) point mutation is
detected in 95.0 % of AGCT patients, especially those
with the diffuse type [18–20]. It has been described that
this point mutation does not reflect immunohistochemi-
cal staining pattern of FOXL2 [20]. In addition, the pat-
tern of reticulin staining is different for these disease
entities. Thus, combination of FOXL2 point mutation
analysis and reticulin staining can be employed in differ-
ential diagnosis of cellular fibroma and AGCT. In this
case, we rejected a diagnosis of AGCT based on FOXL2
mutation analysis and reticulin staining, and confirmed
a final diagnosis of MACF.
Conclusions
We report our experience of a case of rapid growth of a
MACF of the ovary during a 1-year follow-up period.
When preoperative serum tumor marker levels and/or
imaging findings do not suggest ovarian cancer in in-
stances of rapid growth of a solid ovarian mass, MACF
should be considered as a differential diagnosis. Our
case and review of the literature suggest that MACF of
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Abbreviations: α alpha, AD appendectomy, BSO bilateral salpingo-oophorectomy, EMA epithelial membrane antigen, HRP high power field, LD lymph node dissec-
tion, LS laparoscopic surgery, LSO left salpingo-oophorectomy, MF mitotic figure, ND not described, NED no evidence of disease, OMT omentectomy, OT ovarian
tumor, PD preoperative diagnosis, PI proliferative index, PM pelvic mass, RSO right salpingo-oophorectomy, SMA smooth muscle actin, TAH total abdominal hyster-
ectomy, y year, + positive, − negative
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the ovary may represent a heterogeneous disease entity
that requires an accumulation of case reports to estab-
lish diagnosis and treatment.
Abbreviations
AGCT: Adult granulosa cell tumor; MACF: Mitotically active cellular fibroma
Acknowledgements
We wish to thank Editage (https://www.editage.jp) for English language editing.
Funding
This research received no specific financial or material support.
Availability of data and material
All available data are included in the manuscript and its figures.
Authors’ contributions
KM and ST collected clinical data and drafted the manuscript. YA and MN
revised the final version of the manuscript for important intellectual content.
KM and MN conducted the pathological evaluation of the specimen and
assisted in editing the pathology. KM, AK and KY performed the genetic
analysis. ST, SY, SM, AF and TM performed the clinical diagnosis and
treatment. All authors read and approved the final version of the manuscript
prior to submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and any accompanying images. A copy of the consent form
is available on request for review by the Editor of this journal.
Ethics approval and consent to participate
Not applicable.
Author details
1Departments of Tumor and Diagnostic Pathology, Atomic Bomb Disease
Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
2Department of Obstetrics and Gynecology, Japan Community Health Care
Organization, Isahaya General Hospital, Isahaya, Japan. 3Department of
Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki,
Japan. 4Department of Human Genetics, Atomic Bomb Disease Institute,
Nagasaki University, Nagasaki, Japan.
Received: 5 August 2016 Accepted: 15 October 2016
References
1. Tavassoli FA, Devilee P. WHO classification of tumours pathology & genetics
tumours of the breast and female genital organs. IARC: Lyon; 2003.
2. Prat J, Scully RE. Cellular fibromas and fibrosarcomas of the ovary: a
comparative clinicopathologic analysis of seventeen cases. Cancer. 1981;47:
2663–70.
3. Christman JE, Ballon SC. Ovarian fibrosarcoma associated with Maffucci’s
syndrome. Gynecol Oncol. 1990;37:290–1.
4. Huang YC, Hsu KF, Chou CY, Dai YC, Tzeng CC. Ovarian fibrosarcoma with
long-term survival: a case report. Int J Gynecol Cancer. 2001;11:331–3.
5. Krüger S, Schmidt H, Küpker W, Rath FW, Feller AC. Fibrosarcoma associated
with a benign cystic teratoma of the ovary. Gynecol Oncol. 2002;84:150–4.
6. Cinel L, Taner D, Nabaei SB, Oguz S, Gökmen O. Ovarian fibrosarcoma with
five-year survival: a case report. Eur J Gynaecol Oncol. 2002;23:345–6.
7. Lee HY, Ahmed Q. Fibrosarcoma of the ovary arising in a fibrothecomatous
tumor with minor sex cord elements. A case report and review of the
literature. Arch Pathol Lab Med. 2003;127:81–4.
8. Gultekin M, Dursun P, Ozyuncu O, Usubutun A, Yuce K, Ayhan A. Primary
ovarian fibrosarcoma: a case report and review of the literature. Int J
Gynecol Cancer. 2005;15:1142–7.
9. Irving JA, Alkushi A, Young RH, Clement PB. Cellular fibromas of the ovary: a
study of 75 cases including 40 mitotically active tumors emphasizing their
distinction from fibrosarcoma. Am J Surg Pathol. 2006;30:929–38.
10. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of
tumours of female reproductive organs. 4th ed. Lyon: IARC; 2014.
11. Kaku S, Takeshima N, Akiyama F, Furuta R, Hirai Y, Takizawa K. A unique
fibrous tumor of the ovary: fibrosarcoma or mitotically active cellular
fibroma? Anticancer Res. 2007;27:4365–9.
12. Bucella D, Limbosch JF, Buxant F, Simon P, Fayt I, Anaf V, et al. Recurrence
of mitotically active cellular fibroma of the ovary. Obstet Gynecol Int. 2009.
doi:10.1155/2009/803062.
13. Monteiro SB, Costa A, Paiva V. Mitotically active cellular ovarian fibroma with
Meigs’ syndrome and elevated CA-125: towards fertility preservation. J
Pediatr Adolesc Gynecol. 2012;25:e107–9.
14. Wu H, Xie J, Huang W, Wu J. Mitotically active cellular fibroma of the ovary: a
case report and a review of the literature. Eur J Gynaecol Oncol. 2014;35:81–3.
15. Zong L, Lin M, Fan X. Mitotically active cellular fibroma of ovary should be
differentiated from fibrosarcoma: a case report and review of literature. Int J
Clin Exp Pathol. 2014;7:7578–82.
16. Yamada T, Hattori K, Satomi H, Hirose Y, Nakai G, Daimon A, et al. Mitotically
active cellular fibroma of the ovary: a case report and literature review. J
Ovarian Res. 2015;8:65.
17. Choi WJ, Ha MT, Shin JK, Lee JH. Primary ovarian fibrosarcoma with long-
term survival: a report of two cases. J Obstet Gynaecol Res. 2006;32:524–8.
18. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of
FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719–29.
19. Kommoss S, Anglesio MS, Mackenzie R, Yang W, Senz J, Ho J, et al. FOXL2
molecular testing in ovarian neoplasms: diagnostic approach and
procedural guidelines. Mod Pathol. 2013;26:860–7.
20. McCluggage WG, Singh N, Kommoss S, Huntsman DG, Gilks CB. Ovarian cellular
fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction
from diffuse adult granulosa cell tumor. Am J Surg Pathol. 2013;37:1450–5.
21. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian
stromal cell tumors. J Clin Oncol. 2007;25:2944–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Matsuda et al. Diagnostic Pathology  (2016) 11:101 Page 6 of 6
